The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responses

The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responses

Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 255(2023) vom: 01. Okt., Seite 109762
1. Verfasser: Föhse, Konstantin (VerfasserIn)
Weitere Verfasser: Geckin, Büsra, Zoodsma, Martijn, Kilic, Gizem, Liu, Zhaoli, Röring, Rutger J, Overheul, Gijs J, van de Maat, Josephine, Bulut, Ozlem, Hoogerwerf, Jacobien J, Ten Oever, Jaap, Simonetti, Elles, Schaal, Heiner, Adams, Ortwin, Müller, Lisa, Ostermann, Philipp Niklas, van de Veerdonk, Frank L, Joosten, Leo A B, Haagmans, Bart L, van Crevel, Reinout, van Rij, Ronald P, GeurtsvanKessel, Corine, de Jonge, Marien I, Li, Yang, Domínguez-Andrés, Jorge, Netea, Mihai G
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2023
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article BNT162b2 COVID-19 Innate immune response SARS-CoV-2
LEADER 01000naa a22002652 4500
001 NLM361708718
003 DE-627
005 20231226085719.0
007 cr uuu---uuuuu
008 231226s2023 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2023.109762  |2 doi 
028 5 2 |a pubmed24n1205.xml 
035 |a (DE-627)NLM361708718 
035 |a (NLM)37673225 
035 |a (PII)S1521-6616(23)00525-9 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Föhse, Konstantin  |e verfasserin  |4 aut 
245 1 4 |a The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responses 
264 1 |c 2023 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Revised 28.09.2023 
500 |a published: Print-Electronic 
500 |a Citation Status Publisher 
520 |a Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved. 
520 |a The mRNA-based BNT162b2 protects against severe disease and mortality caused by SARS-CoV-2 via induction of specific antibody and T-cell responses. Much less is known about its broad effects on immune responses against other pathogens. Here, we investigated the adaptive immune responses induced by BNT162b2 vaccination against various SARS-CoV-2 variants and its effects on the responsiveness of immune cells upon stimulation with heterologous stimuli. BNT162b2 vaccination induced effective humoral and cellular immunity against SARS-CoV-2 that started to wane after six months. We also observed long-term transcriptional changes in immune cells after vaccination. Additionally, vaccination with BNT162b2 modulated innate immune responses as measured by inflammatory cytokine production after stimulation - higher IL-1/IL-6 release and decreased IFN-α production. Altogether, these data expand our knowledge regarding the overall immunological effects of this new class of vaccines and underline the need for additional studies to elucidate their effects on both innate and adaptive immune responses 
650 4 |a Journal Article 
650 4 |a BNT162b2 
650 4 |a COVID-19 
650 4 |a Innate immune response 
650 4 |a SARS-CoV-2 
700 1 |a Geckin, Büsra  |e verfasserin  |4 aut 
700 1 |a Zoodsma, Martijn  |e verfasserin  |4 aut 
700 1 |a Kilic, Gizem  |e verfasserin  |4 aut 
700 1 |a Liu, Zhaoli  |e verfasserin  |4 aut 
700 1 |a Röring, Rutger J  |e verfasserin  |4 aut 
700 1 |a Overheul, Gijs J  |e verfasserin  |4 aut 
700 1 |a van de Maat, Josephine  |e verfasserin  |4 aut 
700 1 |a Bulut, Ozlem  |e verfasserin  |4 aut 
700 1 |a Hoogerwerf, Jacobien J  |e verfasserin  |4 aut 
700 1 |a Ten Oever, Jaap  |e verfasserin  |4 aut 
700 1 |a Simonetti, Elles  |e verfasserin  |4 aut 
700 1 |a Schaal, Heiner  |e verfasserin  |4 aut 
700 1 |a Adams, Ortwin  |e verfasserin  |4 aut 
700 1 |a Müller, Lisa  |e verfasserin  |4 aut 
700 1 |a Ostermann, Philipp Niklas  |e verfasserin  |4 aut 
700 1 |a van de Veerdonk, Frank L  |e verfasserin  |4 aut 
700 1 |a Joosten, Leo A B  |e verfasserin  |4 aut 
700 1 |a Haagmans, Bart L  |e verfasserin  |4 aut 
700 1 |a van Crevel, Reinout  |e verfasserin  |4 aut 
700 1 |a van Rij, Ronald P  |e verfasserin  |4 aut 
700 1 |a GeurtsvanKessel, Corine  |e verfasserin  |4 aut 
700 1 |a de Jonge, Marien I  |e verfasserin  |4 aut 
700 1 |a Li, Yang  |e verfasserin  |4 aut 
700 1 |a Domínguez-Andrés, Jorge  |e verfasserin  |4 aut 
700 1 |a Netea, Mihai G  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 255(2023) vom: 01. Okt., Seite 109762  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:255  |g year:2023  |g day:01  |g month:10  |g pages:109762 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2023.109762  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 255  |j 2023  |b 01  |c 10  |h 109762